New hope for adults with HLH: gentler treatment combo under study
NCT ID NCT06160791
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of ruxolitinib and a reduced-intensity version of the standard HLH-94 regimen (dexamethasone and etoposide) in 36 adults newly diagnosed with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system attacks the body. The goal is to see if this approach can control the disease with fewer toxic side effects. Participants will receive treatment for up to 4 weeks, and researchers will measure how many respond to therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ruxolitinib, etoposide, dexamethasone
What this could lead to
If successful, this could offer a less toxic treatment option for adults with HLH, potentially improving outcomes while reducing side effects.
What could go wrong
This is a small, early-phase trial (36 participants) with no control group, so results may not be definitive. The combination may still cause serious side effects or fail to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact
Contact Email: •••••@•••••
-
University of California, Irvine
RECRUITINGIrvine, California, 92697, United States
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Email: •••••@•••••